# Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy

> **NCT02216916** · PHASE2 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 49 (estimated)

## Conditions studied

- HNSCC

## Interventions

- **DRUG:** HM781-36B

## Key facts

- **NCT ID:** NCT02216916
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-08
- **Primary completion:** 2019-07
- **Final completion:** 2019-07
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2019-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02216916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02216916, "Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02216916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*